scanX
Alkem Laboratories
add_icon

Alkem Laboratories

5,456.50
-24.00
(-0.44%)
Market Cap
65,240.64 Cr
PE Ratio
27.05
Volume
74,670.00
Day High - Low
5,510.00 - 5,415.50
52W High-Low
5,933.50 - 4,491.65
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
65,240.64 Cr
EPS
181.11
PE Ratio
27.05
PB Ratio
4.91
Book Value
1,142.87
EBITDA
3,005.90
Dividend Yield
0.82 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
17.82
Debt to Equity
0.13
Analyst Rating and Forecast
- By Refinitiv from19 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+42.11 %
+42.11 %
Hold
Hold+36.84 %
+36.84 %
Sell
Sell+21.05 %
+21.05 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Alkem's Enzene unit receives USFDA Form 483 with 6 obs3 days ago
Alkem Laboratories subsidiary Enzene Biosciences received USFDA Form 483 with 6 procedural observations after Pre-Approval Inspection, achieving zero data integrity issues.
positive
Alkem Labs amends Enzene Biosciences agreement4 days ago
Alkem Laboratories enters Amendment cum Supplemental Agreement with Enzene Biosciences and investors for Rs. 26.16 crore fund infusion through preferential allotment of securities.
positive
Alkem Labs to Acquire 51-55% Stake in Swiss Medtech Firm4 days ago
Alkem Laboratories' subsidiary to acquire majority stake in Occlutech Holding AG, a Swiss cardiovascular device manufacturer, for EUR 180.70 million total equity value.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,717.10
#1 4,11,989.81
37.23
#1 54,729.00
9.71
#1 10,980
16.07
57.32
Divis Laboratories
6,187.50
1,64,258.68
65.90
9,712.00
18.67
2,191
-1.02
49.75
Torrent Pharmaceuticals
4,258.40
1,44,123.61
63.47
11,539.40
6.99
1,911
26.24
70.01
Cipla
1,343.90
1,08,556.45
24.16
28,409.50
7.12
5,291
-57.18
42.35
Dr Reddys Laboratories
1,284.80
1,07,233.31
19.18
33,741.20
16.73
5,725
-15.28
61.90
Lupin
2,247.50
1,02,665.53
21.74
22,909.50
13.74
3,306
#1 37.44
64.82
Zydus Life Science
906.65
91,230.20
#1 18.22
23,511.00
18.55
4,615
-0.32
51.72
Mankind Pharma
2,062.90
85,157.56
47.66
12,744.20
#1 20.90
2,007
7.65
42.99
Aurobindo Pharma
1,186.70
68,923.73
19.75
32,345.60
9.43
3,484
7.59
52.29
Alkem Laboratories
5,456.50
#10 65,240.64
#6 27.05
#7 13,458.30
#10 3.70
#7 2,216
#6 1.90
39.54
Growth Rate
Revenue Growth
3.70 %
Net Income Growth
22.33 %
Cash Flow Change
-1.81 %
ROE
5.38 %
ROCE
4.61 %
EBITDA Margin (Avg.)
13.35 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
944
1,244
1,432
1,290
1,252
1,509
1,672
1,507
1,276
1,342
1,889
1,765
1,521
1,686
1,943
1,934
1,882
1,867
2,296
2,210
2,077
2,047
2,398
2,415
2,238
2,778
2,842
2,673
2,504
2,628
3,130
3,086
2,971
3,034
3,503
3,418
3,024
3,152
3,549
3,467
3,290
3,521
4,105
3,880
Expenses
777
1,001
1,127
1,052
993
1,210
1,328
1,214
1,102
1,218
1,405
1,381
1,389
1,455
1,555
1,613
1,619
1,585
1,811
1,729
1,746
1,470
1,762
1,789
1,901
2,139
2,176
2,121
2,162
2,373
2,626
2,442
2,652
2,579
2,751
2,668
2,546
2,423
2,662
2,615
2,753
2,632
3,080
2,962
EBITDA
167
242
306
238
260
299
344
294
174
124
485
384
132
231
388
321
263
282
484
481
331
577
636
626
337
640
666
552
343
255
505
644
319
455
752
750
478
729
887
852
537
889
1,025
918
Operating Profit %
13 %
16 %
17 %
17 %
14 %
18 %
19 %
18 %
12 %
7 %
24 %
21 %
7 %
12 %
19 %
16 %
13 %
14 %
20 %
21 %
15 %
26 %
25 %
23 %
13 %
22 %
22 %
19 %
13 %
8 %
15 %
20 %
9 %
13 %
20 %
20 %
13 %
20 %
22 %
23 %
12 %
22 %
23 %
21 %
Depreciation
18
21
26
23
24
23
26
26
26
31
35
38
40
43
46
48
57
56
56
60
81
67
70
69
69
71
73
78
83
76
77
78
78
72
74
70
83
81
79
85
113
88
94
95
Interest
17
23
20
19
10
10
12
12
11
13
18
15
10
16
16
15
7
16
18
17
14
17
18
13
11
13
12
11
17
27
25
27
29
30
30
26
27
29
28
36
28
30
35
42
Profit Before Tax
150
211
280
213
225
266
307
255
136
81
432
332
81
172
326
258
199
210
410
405
235
493
548
543
258
556
582
464
243
152
402
539
212
353
648
655
367
619
780
731
396
771
896
781
Tax
19
7
8
23
139
23
19
19
-1
17
105
152
15
35
66
53
28
23
29
15
44
70
66
80
9
76
23
-69
135
20
55
79
144
65
33
51
63
69
78
90
74
103
117
128
Net Profit
132
204
272
190
87
243
288
236
137
64
327
181
66
137
260
205
171
187
381
390
192
423
482
464
249
480
559
533
108
131
348
460
68
288
615
604
305
550
702
641
322
668
779
653
EPS in ₹
11.00
16.82
22.32
15.63
7.25
19.97
23.65
19.52
11.46
5.99
26.82
14.36
5.61
11.39
21.28
16.94
14.00
15.51
31.02
31.95
15.79
35.30
39.48
37.72
20.07
39.15
45.52
43.96
9.00
10.68
27.67
38.03
5.94
23.98
51.90
49.76
24.55
45.60
57.60
52.34
25.57
55.56
63.99
53.19
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
5,296
5,535
6,568
7,666
8,208
9,946
11,519
14,069
13,757
15,575
17,691
Fixed Assets
1,374
1,450
1,797
2,284
2,530
2,908
2,793
2,902
2,683
2,873
2,852
Current Assets
2,338
2,769
2,917
4,013
4,216
5,506
6,929
8,434
8,730
10,412
10,811
Capital Work in Progress
111
172
299
381
493
363
393
340
323
159
548
Investments
61
509
553
444
324
261
333
371
622
484
1,846
Other Assets
3,750
3,404
3,919
4,557
4,861
6,413
8,000
10,457
10,129
12,060
12,445
Total Liabilities
5,296
5,535
6,568
7,666
8,208
9,946
11,519
14,069
13,757
15,575
17,691
Current Liabilities
2,006
1,538
1,690
2,383
2,190
3,245
3,604
4,805
3,707
3,995
3,959
Non Current Liabilities
205
210
296
297
446
392
357
417
615
866
1,299
Total Equity
3,085
3,787
4,583
4,985
5,572
6,309
7,558
8,847
9,435
10,714
12,434
Reserve & Surplus
2,975
3,668
4,444
4,840
5,415
6,137
7,353
8,614
9,021
10,288
11,961
Share Capital
24
24
24
24
24
24
24
24
24
24
24
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
39
3
40
0
82
-73
-2
58
42
-208
-186
Investing Activities
-235
205
-294
-351
-318
-737
-995
-1,433
120
-1,011
-1,288
Operating Activities
326
726
471
266
780
585
1,265
1,111
1,683
1,948
1,913
Financing Activities
-52
-927
-138
85
-379
79
-272
380
-1,761
-1,145
-811
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
60.16 %
58.84 %
58.84 %
57.13 %
57.13 %
57.14 %
57.16 %
57.16 %
57.16 %
57.16 %
56.74 %
56.74 %
56.74 %
56.38 %
55.66 %
55.66 %
55.13 %
53.04 %
51.20 %
51.20 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.11 %
8.69 %
9.02 %
10.15 %
9.41 %
9.11 %
9.48 %
9.97 %
DIIs
12.97 %
14.28 %
13.78 %
13.76 %
13.93 %
13.88 %
15.26 %
16.44 %
16.69 %
15.43 %
17.64 %
14.94 %
15.63 %
18.57 %
19.21 %
18.01 %
19.42 %
21.80 %
21.93 %
21.54 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
21.75 %
21.70 %
21.15 %
22.85 %
22.63 %
22.33 %
22.28 %
21.74 %
21.44 %
20.61 %
19.36 %
18.60 %
18.31 %
16.15 %
15.84 %
15.90 %
15.77 %
15.69 %
17.18 %
17.09 %
Others
5.12 %
5.17 %
6.23 %
6.26 %
6.31 %
6.65 %
5.30 %
4.67 %
4.71 %
6.80 %
6.26 %
9.72 %
0.21 %
0.21 %
0.26 %
0.28 %
0.28 %
0.36 %
0.22 %
0.21 %
No of Share Holders
92,594
93,540
87,392
86,881
81,869
84,104
79,721
76,516
73,440
66,790
69,442
65,184
65,830
69,627
74,744
84,038
84,326
79,740
67,196
64,536

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 15 13 16 25 30 34 50 40 45 0.00
Dividend Yield (%) 0.75 0.74 0.69 0.9 0.83 1.03 1.01 0.82 0.82 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
20 Feb 2026 DIVIDEND Dividend
₹ 43.00 /share
 20 Feb 2026 5,858.30 5,480.30
13 Feb 2021 DIVIDEND Dividend
₹ 25.00 /share
 11 Feb 2021 2,975.90 2,868.65
10 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
 09 Aug 2021 2,996.15 3,514.65
12 Feb 2022 DIVIDEND Dividend
₹ 30.00 /share
 10 Feb 2022 3,537.95 3,431.45
10 Aug 2022 DIVIDEND Dividend
₹ 4.00 /share
 08 Aug 2022 2,960.40 2,985.40
18 Feb 2023 DIVIDEND Dividend
₹ 25.00 /share
 17 Feb 2023 3,230.05 3,264.35
18 Feb 2023 DIVIDEND Dividend
₹ 15.00 /share
 17 Feb 2023 3,230.05 3,264.35
10 Aug 2023 DIVIDEND Dividend
₹ 10.00 /share
 10 Aug 2023 3,326.30 4,227.25
17 Feb 2024 DIVIDEND Dividend
₹ 35.00 /share
 16 Feb 2024 5,309.25 5,444.15
10 Aug 2024 DIVIDEND Dividend
₹ 5.00 /share
 09 Aug 2024 5,314.35 5,793.15
30 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 30 Aug 2024 5,314.35 5,998.65
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2024 5,796.25 5,501.35
07 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Feb 2025 4,954.15 5,256.60
14 Feb 2025 DIVIDEND Dividend
₹ 37.00 /share
 14 Feb 2025 5,256.60 4,722.30
29 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 May 2025 5,290.35 5,265.65
08 Aug 2025 DIVIDEND Dividend
₹ 8.00 /share
 08 Aug 2025 5,265.65 4,878.10
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 12 Aug 2025 4,894.80 4,842.40
25 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 25 Aug 2025 5,265.65 5,425.80
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2025 5,550.35 5,765.05
13 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Feb 2026 5,765.40 5,858.30

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation13 hrs ago
Announcement under Regulation 30 (LODR)-Investor Presentation1 day ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript1 day ago
USFDA Inspection At The Manufacturing Facility Of Enzene Biosciences Limited A Subsidiary Of The Company In India Located At Chakan Pune - Update1 day ago
Announcement under Regulation 30 (LODR)-Newspaper Publication3 days ago
USFDA Inspection At The Manufacturing Facility Of Enzene Biosciences Limited A Subsidiary Of The Company In India3 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication4 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication4 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome4 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation4 days ago
Closure of Trading Window4 days ago
Announcement under Regulation 30 (LODR)-Acquisition4 days ago
Announcement under Regulation 30 (LODR)-Updates on Acquisition4 days ago
Corporate Action-Board approves Dividend4 days ago
Announcement Under Regulation 30 (LODR) - Amendment Cum Supplemental Agreement4 days ago
Results- Unaudited Financial Results For Quarter And Nine Months Ended 31St Dec 20254 days ago
Announcement under Regulation 30 (LODR)-Scheme of Arrangement4 days ago
Board Meeting Outcome for Outcome Of The Board Meeting Dated 13Th Feb 20264 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Announcement under Regulation 30 (LODR)-Scheme of ArrangementFeb 06, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 23, 2026
Board Meeting Intimation for Board Meeting Intimation For Notice Of Meeting Of Board Of Directors Of Alkem Laboratories Limited.Jan 23, 2026
Disclosure Under Regulation 30 Of SEBI LODRJan 22, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 17, 2026
Disclosure Under Regulation 30 Of SEBI LODRJan 13, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 08, 2026
Disclosure Under Regulation 30 Of SEBI LODRJan 01, 2026
Announcement under Regulation 30 (LODR)-Updates on AcquisitionDec 30, 2025
Disclosure Under Regulation 30 Of SEBI LODR.Dec 30, 2025
Disclosure Under Regulation 30 Of SEBI LODR.Dec 30, 2025
Disclosure Under Regulation 30 Of SEBI LODR.Dec 30, 2025
Disclosure Under Regulation 30 Of SEBI LODR.Dec 29, 2025
Announcement under Regulation 30 (LODR)-AcquisitionDec 26, 2025
Disclosure Under Regulation 30 Of SEBI.Dec 26, 2025
Closure of Trading WindowDec 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 23, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementDec 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 15, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementDec 12, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 12, 2025
GMP Inspection By Malta Medicines Authority At CompanyS Manufacturing Facility Located At Daman IndiaDec 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementDec 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementDec 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementDec 05, 2025
Disclosure Under Regulation 30 Of SEBI .Dec 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 03, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Quality Fund Direct-Growth
2.74%
-18115
-0.33%
-0.45%
Bandhan Multi-Factor Fund Direct - Growth
0.98%
10732
0.98%
0.98%
Kotak Active Momentum Fund Direct-Growth
1.77%
-527
0.10%
0.11%
JioBlackRock Nifty Midcap 150 Index Fund Direct-Growth
0.89%
305
0.05%
0.06%
Tata Nifty Midcap 150 Index Fund Direct-Growth
0.90%
-154
0.06%
0.06%
Franklin India Multi-Factor Fund Direct - Growth
0.21%
139
0.01%
0.21%
Nippon India Nifty 500 Low Volatility 50 Index Fund Direct-Growth
1.30%
67
0.06%
1.30%
DSP Nifty 500 Index Fund Direct-Growth
0.17%
35
0.17%
0.17%
Kotak Nifty Midcap 150 Index Fund Direct - Growth
0.89%
30
0.05%
0.06%
DSP Nifty Healthcare Index Fund Direct-Growth
3.54%
27
0.26%
0.36%
DSP Nifty Midcap 150 Index Fund Direct - Growth
0.89%
17
0.05%
0.89%
Groww Nifty Midcap 150 Index Fund Direct - Growth
0.89%
15
0.06%
0.05%
Nippon India Nifty India Manufacturing Index Fund Direct - Growth
0.90%
-7
0.05%
0.05%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.58%
6
0.03%
0.58%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.16%
3
0.01%
0.01%
JM Arbitrage Fund Direct-Growth
0.04%
0
0.00%
0.00%
ICICI Prudential ELSS Tax Saver Direct Plan - Growth
1.00%
0
0.00%
-0.56%
Bandhan Aggressive Hybrid Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Arbitrage Fund Direct-Growth
0.00%
0
0.00%
-0.03%
Bandhan BSE Healthcare Index Fund Direct-Growth
2.61%
0
0.00%
0.23%
Bandhan Large & Mid Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Large Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Midcap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Multi Asset Allocation Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Multi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
36.02
ATR(14)
Volatile
160.15
STOCH(9,6)
Neutral
75.57
STOCH RSI(14)
Neutral
64.49
MACD(12,26)
Bearish
-8.74
ADX(14)
Weak Trend
18.07
UO(9)
Bearish
50.01
ROC(12)
Downtrend And Accelerating
-5.43
WillR(14)
Oversold
-87.83
Bearish
3
Neutral
5
Bullish
1

About Alkem Laboratories

Alkem Laboratories Limited is an Indian pharmaceutical company headquartered in Mumbai, with global operations. The company develops, manufactures, and sells pharmaceutical and nutraceutical products, including branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals. It has a portfolio of over 800 brands in India and operates in more than...more
Listing Date
23 Dec, 2015(10 Years, 26 days)
Website
https://www.alkemlabs.com
Chairperson NameBasudeo N Singh
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104